Press Releases Archives - Page 2 of 22

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Global HQ

Press Releases

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

Biocon Academy Conducts its 9th Graduation Day

Biocon Foundation Marks 20 Years of Transforming Lives Through Impactful Social Initiatives

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States

Biocon Foundation Dedicates Metro Pillars Public Art Project to ‘Everyday Champions’ of Bengaluru

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%^# EBITDA at Rs 787 Cr, Up 16%^#; Net Profit at Rs 25 Cr

Biocon’s S&P Global ESG Score Improves to 69 for 2024

Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biocon Biologics Completes One Year as an Integrated Global Biosimilars Enterprise

Agree >>

Agree >>

Agree >>

Press Releases

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

Biocon Academy Conducts its 9th Graduation Day

Biocon Foundation Marks 20 Years of Transforming Lives Through Impactful Social Initiatives

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States

Biocon Foundation Dedicates Metro Pillars Public Art Project to ‘Everyday Champions’ of Bengaluru

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr

Biocon’s S&P Global ESG Score Improves to 69 for 2024

Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biocon Biologics Completes One Year as an Integrated Global Biosimilars Enterprise

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%^# EBITDA at Rs 787 Cr, Up 16%^#; Net Profit at Rs 25 Cr